Diagnostics company making molecular tests that monitor organ transplant patients for rejection risk.
Diagnostics company making molecular tests that monitor organ transplant patients for rejection risk.
Earns per test run in its own labs for transplant centres, billed mostly to Medicare and private insurers rather than to hospitals directly, so insurance coverage and per-test payment rates decide results. Kidney transplant monitoring is the core; heart tests came alongside.
Moat: narrow (IP / patents, data, regulatory licence). Patented, clinically validated transplant-rejection tests with deep transplant-center relationships.
Headquarters: Brisbane, California · Founded: 1998 · Employees: 765
Size CareDx (CDNA) is a United States Health Care company (Medical Specialties) with a market value of $3.91B, the 1351st largest of 3,085 United States companies the cockpit tracks. Shares closed at $74.44 on 18 Nov 2026.
Performance Over six months the shares gained 252.0%, against +11.1% for the median peer and -2.2% for the United States market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 38.9% over the last twelve months (peer median +7.4%); the operating margin is 0.9% (peer median 12.8%).
Valuation It trades at 50.6× forward earnings against a peer median of 21.5× (2nd most expensive of 19).
Capital Return on invested capital runs 16.2 points below its cost of capital (17.5% WACC).
Short interest Short interest is 13.7% of the free float (30 Oct 2026).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $497M | $380M | $334M | $280M | $322M |
| Revenue growth | — | +14% | +19% | -13% | — |
| Gross profit | $351M | $254M | $222M | $176M | $207M |
| EBITDA | $28.0M | -$1.71M | -$33.5M | -$82.1M | -$61.2M |
| Net income | $129M | -$21.4M | $52.5M | -$190M | -$76.6M |
| Free cash flow | $59.8M | $36.1M | $31.6M | -$26.7M | -$46.5M |
| Capital expenditure | $9.26M | $6.59M | $6.48M | $9.24M | $24.3M |
| Total debt | $29.0M | $26.2M | $28.4M | $34.2M | $39.0M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| CareDx CDNA | $3.91B | +252% | +39% | 1% | 50.6× | n/a |
| Natera NTRA | $42.0B | +41% | +37% | -9% | n/a | n/a |
| Thermo Fisher Scientific TMO | $257B | +53% | +8% | 19% | 25.7× | 21.3% |
| Eurofins Scientific ERF.PA | $16.4B | +37% | +3% | 12% | 22.1× | 12.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CDNA | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +7.6% | +3.5% | 9th highest of 21 |
| 6-month return | +252.0% | +11.1% | highest of 21 |
| Distance from 52-week high | -18.1% | -22.1% | 9th highest of 21 |
| Revenue growth (TTM) | +38.9% | +7.4% | 3rd highest of 21 |
| Operating margin | 0.9% | 12.8% | 5th lowest of 20 |
| Forward P/E | 50.6× | 21.5× | 2nd most expensive of 19 |
| ROIC minus cost of capital | -16.2 pp | -0.0 pp | 3rd lowest of 19 |
| Net debt / EBITDA | -7.9× | 1.0× | least indebted of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| CareDx CDNA | United States | $3.91B | +252% | +39% | 1% | 50.6× | n/a | n/a |
| Fielmann FIE.DE | Germany | $3.92B | -3% | +3% | 14% | 17.1× | -5.5% | +11.3% |
| Andon Health 002432.SZ | China | $3.86B | -24% | -30% | -26% | 16.1× | -6.6% | -7.4% |
| Envista NVST | United States | $3.81B | 0% | +10% | 12% | 14.7× | 4.8% | +7.1% |
| SCHOTT Pharma AG & Co. KGaA 1SXP.DE | Germany | $3.73B | +32% | +4% | 15% | 23.0× | 12.7% | +11.0% |
| Jiangsu Yuyue Medical Equipment & Supply 002223.SZ | China | $4.18B | -3% | -1% | 13% | 20.0× | 4.9% | +3.4% |
| Stevanato STVN | United States | $4.19B | -13% | +12% | 18% | 22.5× | 13.1% | +12.1% |
| Shandong Weigao Blood Purification Products 603014.SS | China | $3.63B | -1% | +4% | n/a | 20.4× | -1.2% | +8.1% |
| Tecan TECN.SW | Switzerland | $3.60B | +59% | -4% | 1% | 35.5× | 45.4% | +3.8% |
| Sumitomo Bakelite 4203.T | Japan | $3.50B | +7% | +15% | 13% | 15.9× | 8.6% | +8.9% |
| Ambu A/S AMBU-B.CO | Denmark | $3.47B | +31% | +7% | 13% | 28.8× | 10.0% | +10.0% |
| ICU Medical ICUI | United States | $4.46B | +38% | -6% | 8% | 19.4× | 18.9% | +11.9% |
| Axogen AXGN | United States | $3.40B | +33% | +24% | -5% | 87.3× | 52.6% | +14.9% |
| Pulse Biosciences PLSE | United States | $3.37B | +76% | +1,637% | -5,821% | n/a | n/a | n/a |
| Autobio Diagnostics 603658.SS | China | $3.36B | +16% | +3% | 25% | 20.3× | -0.4% | +7.2% |
| TransMedics TMDX | United States | $3.35B | +42% | +28% | 12% | 43.4× | 38.4% | +88.2% |
| GRAIL GRAL | United States | $4.59B | +67% | +17% | -332% | n/a | n/a | n/a |
| iRay Technology 688301.SS | China | $3.31B | -30% | +58% | 24% | 25.7× | n/a | n/a |
| Sotera Health SHC | United States | $4.65B | +5% | +7% | 37% | 15.7× | 14.4% | +7.3% |
| Zhende Medical 603301.SS | China | $3.26B | -10% | +8% | 7% | 42.5× | 22.9% | -16.1% |
| MiniMed MMED | United States | $4.78B | +46% | +14% | 14% | 26.3× | n/a | n/a |